Edition:
United Kingdom

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

2.81USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
136,496
52-wk High
$3.34
52-wk Low
$0.92

Select another date:

Tue, Apr 17 2018

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

BRIEF-ArQule Reports Q4 Loss Per Share $0.09

* ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China

* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA

BRIEF-ArQule Files For Offering Of Up To 17.1 Million Shares

* ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: (http://bit.ly/2ivqMQn) Further company coverage:

BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor

* Arqule announces dosing in a registrational trial of fgfr inhibitor, derazantinib, for treatment of intrahepatic cholangiocarcinoma

BRIEF-Arqule reports Q3 loss per share $0.09

* Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

BRIEF-ArQule announces $9.5 mln private placement of preferred stock

* ArQule announces $9.5 million private placement of preferred stock

Select another date: